Pregabalin + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Central Neuropathic Pain

Conditions

Central Neuropathic Pain

Trial Timeline

Aug 1, 2006 → Sep 1, 2008

NCT ID

NCT00313820

About Pregabalin + Placebo

Pregabalin + Placebo is a approved stage product being developed by Pfizer for Central Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00313820. Target conditions include Central Neuropathic Pain.

What happened to similar drugs?

3 of 19 similar drugs in Central Neuropathic Pain were approved

Approved (3) Terminated (2) Active (14)

🔄Placebo + MirogabalinDaiichi SankyoPhase 3

✅amphotericin B liposomal (Ambisome)Astellas PharmaApproved

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄Leuprolide Acetate (LA)AbbViePhase 3

🔄temozolomideMerckPhase 3

🔄ranibizumab + ranibizumabNovartisPhase 3

🔄Ranibizumab 0.5 mgNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03407430	Phase 2	Terminated	Jan 27, 2016	Jul 20, 2017	Breast Cancer
NCT02607254	Phase 2	Completed	Sep 1, 2015	Jul 1, 2018	Idiopathic Small Fiber Neuropathy
NCT01701362	Phase 3	Completed	Oct 1, 2012	Aug 1, 2015	Neuropathic Pain
NCT01387607	Phase 3	Completed	Feb 6, 2012	Oct 31, 2016	Fibromyalgia
NCT01455415	Phase 3	Completed	Dec 1, 2011	Dec 1, 2013	Painful Diabetic Peripheral Neuropathy
NCT01432236	Phase 3	Completed	Oct 1, 2011	Jul 1, 2013	Fibromyalgia
NCT01271660	Phase 3	Completed	Jul 1, 2011	Mar 1, 2018	Muscle Cramp
NCT01271933	Phase 3	Completed	Mar 1, 2011	Jul 1, 2012	Fibromyalgia
NCT01270828	Phase 3	Completed	Mar 1, 2011	Nov 1, 2014	Post Herpetic Neuralgia
NCT01049217	Phase 3	Terminated	Apr 1, 2010	May 1, 2012	Neuropathy
NCT00977197	Phase 2	Completed	Mar 1, 2010	Jun 1, 2015	Irritable Bowel Syndrome
NCT00883740	Phase 3	Completed	Jun 1, 2009	Jun 1, 2010	Fibromyalgia
NCT00762099	Approved	UNKNOWN	May 1, 2009	Dec 1, 2011	Anxiety
NCT00852436	Phase 2	Terminated	Feb 1, 2009	Oct 1, 2010	Neuropathic Pain
NCT00994786	Approved	Completed	Jan 1, 2009	Jan 1, 2019	Obsessive-Compulsive Disorder
NCT00631696	Approved	Completed	Feb 1, 2008	Feb 1, 2012	Healthy
NCT00584376	Approved	Completed	Dec 1, 2007	Nov 1, 2010	Essential Tremor
NCT00380874	Approved	Terminated	Jan 1, 2007	Mar 1, 2008	Chemotherapy-Induced Peripheral Neuropathy
NCT00381095	Approved	Terminated	Dec 1, 2006	Oct 1, 2010	Bone Neoplasms
NCT00413010	Phase 3	Completed	Dec 1, 2006	Mar 1, 2008	Generalized Anxiety Disorder

Competing Products

20 competing products in Central Neuropathic Pain

See all competitors

Product	Company	Stage	Hype Score
Placebo + Mirogabalin	Daiichi Sankyo	Phase 3	40
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
amphotericin B liposomal (Ambisome)	Astellas Pharma	Approved	43
Methotrexate + Ibrutinib + Temozolomide	Sun Pharmaceutical	Phase 2	31
alcohol + placebo + alcohol + perampanel + perampanel + alcohol + placebo + alcohol	Eisai	Phase 1	29
perampanel	Eisai	Phase 2	35
Tirabrutinib + Placebo	Ono Pharmaceutical	Phase 2	42
Tirabrutinib	Ono Pharmaceutical	Phase 1	36
ONO-4059 + Rituximab + Methotrexate + Procarbazine + Vincristine	Ono Pharmaceutical	Phase 1	33
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	47
Tirabrutinib + Tirabrutinib + Tirabrutinib	Ono Pharmaceutical	Phase 2	39
pemetrexed	Eli Lilly	Phase 1	29
HRS-9231 + Gadobutrol	Jiangsu Hengrui Medicine	Phase 2	42
Leuprolide Acetate (LA)	AbbVie	Phase 3	40
Acalabrutinib	AstraZeneca	Phase 2	39
Durvalumab + Acalabrutinib	AstraZeneca	Phase 1	33
Avelumab + Lenvatinib	Merck	Phase 1	33
temozolomide	Merck	Phase 3	44
Ibrutinib + Pembrolizumab + Rituximab	Merck	Phase 1/2	39
Temozolomide	Merck	Phase 2	35